5.32

6.67% -0.38

After Hours: 5.34 0.02 +0.38%

Insight Molecular Diagnostics Inc (IMDX)

Overview News Price History Discussions Forecast

Insight Molecular Diagnostics Inc stock is traded at $5.32, with a volume of 266.28K. It is down -6.67% in the last 24 hours and down -17.00% over the past month. Insight Molecular Diagnostics Inc is a pioneering diagnostics technology company whose mission is to democratize access to novel molecular diagnostic testing to improve patient outcomes. The Company's flagship technology quantifies a molecular biomarker known as donor-derived cell-free DNA (dd-cfDNA). It is also in the process of rebranding its RUO test kit, GraftAssure, as GraftAssureIQ, and rebranding its future in-vitro diagnostic (IVD) test kit as GraftAssureDx. The company geographically operates in the United States, the United Kingdom, Europe, and the Asia-Pacific regions, with maximum revenue generated from the USA.

Previous Close:

$5.70

Open:

$5.7

24h Volume:

266.28K

Relative Volume:

0.73

Market Cap:

$171.78M

Revenue:

$4.06M

Net Income/Loss:

$-50.22M

P/E Ratio:

-3.287

EPS:

-1.6185

Net Cash Flow:

$-25.37M

1W Performance:

-9.06%

1M Performance:

-17.00%

6M Performance:

+4.31%

1Y Performance:

+0.00%

1-Day Range:

$5.21

$5.70

1-Week Range:

$5.21

$6.19

52-Week Range:

$2.33

$8.51

Insight Molecular Diagnostics Inc Stock (IMDX) Company Profile

Name

Insight Molecular Diagnostics Inc

Sector

Healthcare (1107)

Industry

Diagnostics & Research (50)

Phone

949-409-7600

Address

2 INTERNATIONAL PLAZA DR., SUITE 510, NASHVILLE

Employee

Twitter

Next Earnings Date

2026-05-13

Latest SEC Filings

IMDX's Discussions on Twitter

Compare IMDX vs TMO, DHR, IDXX, A, WAT

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
IMDX Insight Molecular Diagnostics Inc	5.32	184.05M	4.06M	-50.22M	-25.37M	-1.6185
TMO Thermo Fisher Scientific Inc	472.63	176.04B	45.20B	6.87B	6.75B	18.19
DHR Danaher Corp	181.35	128.18B	24.78B	3.68B	5.29B	5.1743
IDXX Idexx Laboratories Inc	573.00	44.96B	4.45B	1.10B	1.06B	13.59
A Agilent Technologies Inc	128.34	36.88B	7.23B	1.41B	1.09B	4.979
WAT Waters Corp	360.54	35.13B	3.77B	449.25M	240.68M	7.8556

Insight Molecular Diagnostics Inc Stock (IMDX) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Mar-28-25	Initiated	Lake Street	Buy
May-24-22	Downgrade	Stephens	Overweight → Equal-Weight
Mar-14-22	Downgrade	KeyBanc Capital Markets	Overweight → Sector Weight
Jan-07-22	Initiated	Stephens	Overweight
Jan-06-22	Resumed	Piper Sandler	Overweight
Mar-17-21	Resumed	Needham	Buy
Jan-07-21	Upgrade	The Benchmark Company	Speculative Buy → Buy
Dec-16-20	Upgrade	Piper Sandler	Neutral → Overweight
Nov-30-20	Initiated	BTIG Research	Buy
Nov-10-20	Initiated	KeyBanc Capital Markets	Overweight
Jul-30-20	Reiterated	The Benchmark Company	Speculative Buy
Jul-01-20	Downgrade	Piper Sandler	Overweight → Neutral
Jun-30-20	Downgrade	Chardan Capital Markets	Buy → Neutral
Jun-02-20	Initiated	Needham	Buy
Feb-13-19	Initiated	Piper Jaffray	Overweight
Jan-29-19	Upgrade	Janney	Neutral → Buy
Dec-19-18	Resumed	Lake Street	Buy

View All

Insight Molecular Diagnostics Inc Stock (IMDX) Latest News

Jun 15, 2026

[Form 4] Insight Molecular Diagnostics Inc. Insider Trading Activity - Stock Titan

Jun 15, 2026

Director Arno Andrew of Insight Molecular (IMDX) receives 32,331-share stock grant - Stock Titan

Jun 15, 2026

Jun 12, 2026

Insight Molecular Diagnostics Inc. (NASDAQ: IMDX) Stock Price, News & Analysis - Kalkine

Jun 12, 2026

IMDX Q1 2026 Earnings: Narrowing Losses with 55% EPS Surprise Amid Revenue DisclosuresBuyback Announcement Report - newsline.com

Jun 12, 2026

Jun 11, 2026

Insight Molecular Diagnostics Inc. Announces Publication of GraftAssure CM-Score Demonstrating Superior Performance in Transplant Rejection Monitoring - Quiver Quantitative

Jun 11, 2026

IMDX GraftAssure Assay Sets New Standard in Screening - GlobeNewswire

Jun 11, 2026

Study: New kidney transplant model doubles reliability of positive results - Stock Titan

Jun 11, 2026

Jun 09, 2026

IMDX Q1 2026 Earnings: EPS Beat Lifts Sentiment Despite No RevenueForward EPS Estimate - newsline.com

Jun 09, 2026

Insight Molecular Diagnostics Inc Highlights Graftassure Technology and Announces Grant Winners At American Transplant Congress - marketscreener.com

Jun 09, 2026

iMDx to Showcase GraftAssure Technology at American Transplant Congress and Announce Research Grant Winners - Quiver Quantitative

Jun 09, 2026

iMDx to Highlight In-House Transplant Testing Opportunity and Host Key Opinion Leaders at American Transplant Congress - The Manila Times

Jun 09, 2026

In-house transplant rejection test heads to key Boston conference - Stock Titan

Jun 09, 2026

Lake Street Maintains Insight Molecular Diagnostics(IMDX.US) With Buy Rating, Maintains Target Price $12 - Moomoo

Jun 09, 2026

Jun 05, 2026

12 Health Care Stocks Moving In Friday's After-Market Session - Benzinga

Jun 05, 2026

Jun 04, 2026

IMDX Q1 2026 Earnings: Strong EPS Beat Driven by Cost Discipline and Operational EfficiencyEarnings Decline Risk - newsline.com

Jun 04, 2026

May 28, 2026

Insight Molecular Diagnostics (IMDX) Posts Modest Gain; Resistance Test LoomsFactor Crowding - newsline.com

May 28, 2026

May 27, 2026

IMDX Q1 2026 Earnings: EPS beats estimates by 55% despite revenue absenceFiscal Year Earnings - newsline.com

May 27, 2026

May 26, 2026

Insight Molecular Diagnostics (IMDX) Rallies 5.75% as Bullish Momentum Builds Near Key ResistanceSynthetic Short - newsline.com

May 26, 2026

May 24, 2026